News
TNYA
2.410
+24.23%
0.470
Pre-Market Most Active for Nov 4, 2024 : TSLL, TNYA, NVDA, DJT, SQQQ, SHV
NASDAQ · 18h ago
Weekly Report: what happened at TNYA last week (1028-1101)?
Weekly Report · 22h ago
Morgan Stanley Predicts Up to 670% Jump for These 2 ‘Strong Buy’ Stocks
TipRanks · 2d ago
Weekly Report: what happened at TNYA last week (1021-1025)?
Weekly Report · 10/28 09:22
Optimistic Outlook for Tenaya Therapeutics Amid Positive Trial Developments for TN-201
TipRanks · 10/22 07:55
TD Cowen Sticks to Their Buy Rating for Tenaya Therapeutics (TNYA)
TipRanks · 10/21 11:46
Weekly Report: what happened at TNYA last week (1014-1018)?
Weekly Report · 10/21 09:22
Promising Developments and DSMB Approval Drive Buy Rating for Tenaya Therapeutics
TipRanks · 10/18 15:25
Tenaya Therapeutics Price Target Maintained With a $16.00/Share by Canaccord Genuity
Dow Jones · 10/18 14:45
Tenaya Therapeutics Is Maintained at Buy by Canaccord Genuity
Dow Jones · 10/18 14:45
Analysts Are Bullish on These Healthcare Stocks: Tenaya Therapeutics (TNYA), Sana Biotechnology (SANA)
TipRanks · 10/18 11:20
Analysts Are Bullish on Top Healthcare Stocks: Tenaya Therapeutics (TNYA), Elevance Health (ELV)
TipRanks · 10/18 11:10
Tenaya Therapeutics Price Target Maintained With a $18.00/Share by HC Wainwright & Co.
Dow Jones · 10/18 11:00
HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $18 Price Target
Benzinga · 10/18 10:50
Tenaya Therapeutics (TNYA) Receives a Buy from Piper Sandler
TipRanks · 10/18 10:36
Positive Buy Rating for Tenaya Therapeutics Amid Progress in TN-201 Gene Therapy and Clinical Trial Advancements
TipRanks · 10/18 10:16
Tenaya Therapeutics provides updates on MyPEAK-1 clinical trial of TN-201
TipRanks · 10/17 20:40
Tenaya Therapeutics Shares Updates Related To Its Ongoing Phase 1b/2 MyPEAK-1 Clinical Trial Of TN-201; TN-201 Has Appropriate Tolerability Profile At 3E13 vg/kg Dose Without Unexpected Adverse Reactions
Benzinga · 10/17 20:34
TENAYA THERAPEUTICS : INDEPENDENT DATA SAFETY & MONITORING BOARD ENDORSED DOSE ESCALATION & BROADENING OF ELIGIBILITY CRITERIA; COHORT 2 NOW ENROLLING
Reuters · 10/17 20:30
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM
Barchart · 10/17 15:30
More
Webull provides a variety of real-time TNYA stock news. You can receive the latest news about Tenaya Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TNYA
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.